Illumina, Inc. (NasdaqGS:ILMN) is seeking financing. It is planning to raise in excess of $1 billion in Series B funding. It intends to use the proceeds from Series B funding for continued development and validation of their blood-based test for cancer screening and repurchase a portion of its stake.